Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

News & Events

Breadcrumb

  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 22 February 2021

    ORYZON reports results and corporate update for 4th quarter and year ended December 31, 2020

  • 11 February 2021

    ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia

  • 10 February 2021

    ORYZON to present new clinical data and corporate updates at conferences in February and March

  • 4 January 2021

    ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021

  • 17 December 2020

    ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry

  • 7 December 2020

    ORYZON presents new robust Phase II iadademstat efficacy data in AML at ASH-2020

  • 11 November 2020

    ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology

  • 10 November 2020

    ORYZON receives approval to start PORTICO Phase IIb trial with vafidemstat in Borderline Personality Disorder

  • 2 November 2020

    Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes

  • 26 October 2020

    ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Next page Next ›
  • Last page Last »

Email alerts

Subscribe and stay up to date with our latest news

Subscribe
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy